pharmaphorum1h
BridgeBio gets EU nod for ATTR cardiomyopathy drug
The EU is the second market for the drug after the US, where it was approved under the Attruby brand name last November, on ...
pharmaphorum1h
Storybook can help kids understand rare kidney disease
Recognising that challenge, AstraZeneca's rare disease unit Alexion has launched an interactive storybook that can help ...
pharmaphorum3h
Trump 'fired Inspector General over critical USAID report'
Martin, who was appointed as Inspector General for the USAID towards the end of 2023 by former President Joe Biden, was dismissed via an email from Trent Morse, deputy director of the White House ...
pharmaphorum23h
5 takeaways from Super Bowl LIX: What health and pharma can learn from it
Super Bowl ads aren’t just entertainment; they’re cultural barometers. They reflect what resonates with audiences, what ...
pharmaphorum23h
Ten years on, Roche jettisons InterMune and Esbriet in US
Roche's sale of InterMune and Esbriet in the US comes as Boehringer revealed its own follow-up play in the IPF, category, ...
pharmaphorum23h
Novartis builds in cardiovascular with $3.1bn Anthos buy
Novartis has agreed to buy Anthos Therapeutics from private equity firm Blackstone for $3.1 billion, adding a drug in ...
pharmaphorum23h
Looking beyond the scale: Why measures of physical activity should be incorporated into obesity trials to support long-term sustainable weight loss
This can help individuals feel fuller for longer and can promote weight loss. When measured by traditional weight loss ...